![]() Good therapeutic control of VKA treatment, with regular prothrombin time (PT) tests reported as International Normalized Ratio (INR) within intended therapeutic range (TR) is imperative for minimizing adverse events (bleeding and/or thrombosis). In Sweden, the number of VKA-treated patients is approaching 200,000, almost 2% of the population, and the treatment is almost exclusively warfarin. The introduction of new therapies emphasizes the need to discern the best practice for patients remaining on warfarin treatment. Although new drugs are being introduced, vitamin K antagonists (VKA) still predominate. The numbers of patients on OAT is steadily increasing worldwide. Oral anticoagulant therapy (OAT) is used to prevent thrombosis in patients with atrial fibrillation (AF), venous thrombosis and prosthetic heart valves. As patient characteristics differ between the PHCC and ACC, it is important to conduct further randomized studies to discern the best practice locally for warfarin management also after the introduction of new drugs. In this study both settings achieved good therapeutic control of warfarin treatment with a minor advantage for PHCC over ACC, and better results for men, especially in the PHCC setting. PT-INR above intended TR was significantly more common in the ACC setting, (p<0.05), for women overall (p<0.01), for women in the PHCC setting, and for ACC men (p<0.05). 63%, p<0.001) and particularly in the PHCC group v. Men generally had better results than women (72% v. Seventy-two percent of PHCC patients and 66% of ACC patients had a PT-INR within the intended TR (p<0.05). The reasons for treating differed between the groups. 70 years (p<0.01) with a predominance of men in both groups. The PHCC patients were older than the ACC patients, 76 v. Mann–Whitney Rank Sum Test and Chi 2 test were used for statistical comparisons. Therapeutic control was calculated as PT test results in relation to intended therapeutic range (TR). ![]() Prothrombin time (PT) test results reported as International Normalized Ratio (INR) were collected for five consecutive days from patients on warfarin treatment 564 PHCC and 927 ACC patients. This study compares patient characteristics and therapeutic control in two settings managing warfarin treatment: Swedish primary health care centers (PHCC) and specialized anticoagulation clinics (ACC). The introduction of new therapies emphasizes the need to discern the best practice for the patients remaining on warfarin treatment. ![]() ![]() Oral anticoagulant therapy is used to prevent thrombosis in patients with atrial fibrillation (AF), venous thrombosis and prosthetic heart valves. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |